Board of directors

Sol-Gel directors includes industry veterans as well as world-leading scientists in the fields of dermatology, pharmaceuticals and microencapsulation. Years of applied experience, and deep cross-functional expertise equips Sol-Gel with unique qualities and capabilities.

doctor-2
Mr. Haim Bar-Simantov
Chief Technology Officer

Mr. Haim Barsimantov has served as our chief technology officer since September 2016. From 2000 until 2007, Mr. Barsimantov served as our plant manager. Since 2007 and until August 2016, Mr. Barsimantov served as our chief operating officer.

doctor-2
Ms. Ofra Levy-Hacham
VP Quality Assurance and Regulatory Affairs

Ms. Ofra Levy-Hacham has served as our vice president of quality and regulatory affairs since 2011. Prior to joining Sol-Gel, Ms. Levy-Hacham served as a scientific specialist and project manager at Biotechnology General Ltd., a fully integrated biopharmaceutical services private company from 2010 until 2011. From 2008 until 2010, Ms. Levy-Hacham served as the vice president chemistry, manufacturing and controls at HealOr Ltd., a private company engaging in the development of therapeutics for the treatment of various skin lesions and conditions. Ms. Levy-Hacham holds a Ph.D. in chemistry from The Technion - Israel Institute of Technology, Haifa, Israel.

doctor-2
Mr. Ofer Toledano
VP Research and Development

Mr. Ofer Toledano has served as our vice president of research and development since 2004. Prior to joining Sol-Gel, Mr. Toledano served as manager of the formulation department at ADAMA Agricultural Solutions Ltd. (formerly known as Makhteshim Agan Industries Ltd.), an Israeli manufacturer and distributor of crop protection products from 1998 until 2004. Mr. Toledano holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel.

doctor-2
Mr. Alon Seri-Levy
Co-Founder and Chief Executive Officer

Mr. Alon Seri-Levy co-founded Sol-Gel and has served as our chief executive officer since our inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-Gel, Mr. Seri-Levy established the computer-aided drug design department at Peptor Ltd., an Israeli research and development company specialized in the development of peptide-based drug products. Mr. Seri-Levy holds a Ph.D. in Chemistry (summa cum laude) from The Hebrew University of Jerusalem, Israel, and conducted his post-doctoral studies at Oxford University, United Kingdom.

doctor-2
Mr. Moshe (Mori) Arkin
Chairman

Mr. Moshe Arkin has served as chairman of our board of directors since 2014. Mr. Moshe Arkin currently sits on the board of directors of several health care companies including Exalenz Bioscience Ltd. (TASE:EXEN), a developer of advanced systems for gastrointestinal and liver disorders since 2006, Quiet Therapeutics Ltd., a cancer drug discovery and development and SoniVie Ltd., a private company developing systems for the treatment of pulmonary arterial hypertension. From 2005 to 2008, Mr. Arkin served as the head of generics at Perrigo Company (NYSE:PRGO; TASE:PRGO) and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining us, Mr. Arkin served as a director of cCAM Biotherapeutics Ltd., a company focused on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck & Co., Inc. (NYSE:MRK). Mr. Moshe Arkin served as chairman of Agis Industries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005. Mr. Moshe Arkin holds a B.A. in psychology from the Tel Aviv University, Israel.

doctor-2
בדיקה
CEO

microencapsulation delivery system, consisting of microcapsules made of precipitated silica. Based on our pre-clinical and clinical data, we expect this delivery system will enable us to develop and commercialize dermatological drug products that are more effective or have fewer side effects than currently marketed drugs.

doctor-2
Media Confidence Index

Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing and coializing topical dermatological drug products.
Sol-Gel is a clinical-stage specialty pharmaceutical company focused  commercializing dermatolol drug products.eveloping and commercializing topical dermatological dru
ing topiatological dru

doctor-2
Dr.Addison_Alexander
VP Quality Assurance and Regulatory Affair

Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing and coializing topical dermatological drug products.
Sol-Gel is a clinical-stage specialty pharmaceutical company focused  commercializing dermatolol drug products.eveloping and commercializing topical dermatological dru
ing topiatological dru
 

doctor-2
Media Derived Indicators
fgas

הלחעדלחכי דגשלחילח ידשלךיכע חלשדי חלשדי ךלשילךהילךסבה לךש ןעטשולהילך ןשדי ןשגיעןשילך שידגליה לשדגח גךלכע שגכעשדגכעש גכע שגכ ע

doctor-2
Earnings Prediction Technology

Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing and coializing topical dermatological drug products.
Sol-Gel is a clinical-stage specialty pharmaceutical company focused  commercializing dermatolol drug products.eveloping and commercializing topical dermatological druing topiatological dru